Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors

被引：5

作者：

Aly, Ragia ^{[1
]}

Aujla, Amandeep S. ^{[2
]}

Gupta, Sachin ^{[3
]}

Gupta, Ruby ^{[4
]}

Gupta, Sorab ^{[5
]}

Kalathil, Sheila ^{[6
]}

机构：

[1] Danbury Hosp, Dept Internal Med, 24 Hosp Ave, Danbury, CT 06810 USA

[2] Hartford Healthcare Canc Inst, Dept Hematol & Med Oncol, 326 Washington St, Norwich, CT 06360 USA

[3] Tower Hlth Reading Hosp, West Reading Hosp, Dept Internal Med, 420 S 5th Ave, W Reading, PA 19611 USA

[4] William Beaumont Hosp, Dept Hematol & Med Oncol, Royal Oak, MI 48073 USA

[5] Bronx Care Hosp, Dept Hematol & Med Oncol, 1650 Grand Concourse, Bronx, NY 10457 USA

[6] Einstein Med Ctr, Dept Hematol & Med Oncol, 5501 Old York Rd, Philadelphia, PA 19141 USA

来源：

WORLD JOURNAL OF ONCOLOGY | 2020年 / 11卷 / 05期

关键词：

Sarcomatoid; Renal cell carcinoma; Immune checkpoint inhibitors; Sunitinib; EXPRESSION; PD-L1;

D O I：

10.14740/wjon1325

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal cell carcinoma (RCC) is a common cancer that affects a significant number of patients every year around the world. The presence of sarcomatoid features in these tumors is considered a poor prognostic feature. Patients with RCC with sarcomatoid features had significantly worse outcomes when treated with sunitinib, the previous first-line standard of care therapy when compared to patients without such features. Multiple immune checkpoint inhibitors have recently been approved for the treatment of RCC. In this article, we review the literature available on the outcomes of patients with sarcomatoid RCC treated with immune checkpoint inhibitors.

引用

页码：183 / 187

页数：5

共 33 条

[11] PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation [J].

Joseph, Richard W. ;

Millis, Sherri Z. ;

Carballido, Estrella M. ;

Bryant, David ;

Gatalica, Zoran ;

Reddy, Sandeep ;

Bryce, Alan H. ;

Vogelzang, Nicholas J. ;

Stanton, Melissa L. ;

Castle, Erik P. ;

Ho, Thai H. .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) :1303-1307

[12] Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation [J].

Kawakami, Fumi ;

Sircar, Kanishka ;

Rodriguez-Canales, Jaime ;

Fellman, Bryan M. ;

Urbauer, Diana L. ;

Tamboli, Pheroze ;

Tannir, Nizar M. ;

Jonasch, Eric ;

Wistuba, Ignacio I. ;

Wood, Christopher G. ;

Karam, Jose A. .

CANCER, 2017, 123 (24) :4823-4831

[13]

Kyriakopoulos Christos E, 2015, Clin Genitourin Cancer, V13, pe79, DOI 10.1016/j.clgc.2014.08.011

[14] Sarcomatoid renal cell carcinoma: a case report and literature review [J].

Liang, Xiang ;

Liu, Yupin ;

Ran, Pengcheng ;

Tang, Meili ;

Xu, Changlei ;

Zhu, Yazhen .

BMC NEPHROLOGY, 2018, 19

[15]

Merrill MM, 2015, UROL ONCOL, V33, P166, DOI DOI 10.1016/J.UR0L0NC.2014.11.021

[16] Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma [J].

Mian, BM ;

Bhadkamkar, N ;

Slaton, JW ;

Pisters, PWT ;

Daliani, D ;

Swanson, DA ;

Pisters, LL .

JOURNAL OF UROLOGY, 2002, 167 (01) :65-70

[17]

Moch H, WHO classification of tumours of the urinary system and male genital organs

[18] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

[19] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Penkov, Konstantin ;

Haanen, John ;

Rini, Brian ;

Albiges, Laurence ;

Campbell, Matthew T. ;

Venugopal, Balaji ;

Kollmannsberger, Christian ;

Negrier, Sylvie ;

Uemura, Motohide ;

Lee, Jae L. ;

Vasiliev, Aleksandr ;

Miller, Wilson H., Jr. ;

Gurney, Howard ;

Schmidinger, Manuela ;

Larkin, James ;

Atkins, Michael B. ;

Bedke, Jens ;

Alekseev, Boris ;

Wang, Jing ;

Mariani, Mariangela ;

Robbins, Paul B. ;

Chudnovsky, Aleksander ;

Fowst, Camilla ;

Hariharan, Subramanian ;

Huang, Bo ;

di Pietro, Alessandra ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) :1103-1115

[20] Prognostic value of histologic subtypes in renal cell carcinoma:: A multicenter experience [J].

Patard, JJ ;

Leray, E ;

Rioux-Leclercq, N ;

Cindolo, L ;

Ficarra, V ;

Zisman, A ;

De La Taille, A ;

Tostain, J ;

Artibani, W ;

Abbou, CC ;

Lobel, B ;

Guillé, F ;

Chopin, DK ;

Mulders, PFA ;

Wood, CG ;

Swanson, DA ;

Figlin, RA ;

Belldegrun, AS ;

Pantuck, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2763-2771

← 1 2 3 4 →